Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

NCT05244798 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

420

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Sintilimab
RADIATION: radiotherapy
DRUG: Chemotherapy

Sponsor

Sichuan Cancer Hospital and Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]